Sermorelin
Sermorelin is a synthetic analog of the first 29 amino acids of growth hormone releasing hormone (GHRH 1-29). Unlike HGH, it stimulates the pituitary to produce GH in a pulsatile, physiological manner rather than delivering exogenous GH. FDA-approved for pediatric GH deficiency diagnosis and treatment; widely prescribed off-label by anti-aging and longevity physicians. Advantages over exogenous HGH: preserves pituitary function, more physiological GH pulses, lower feedback suppression, significantly lower cost. Often combined with GHRP-2 or ipamorelin to maximize GH pulse amplitude via dual-axis stimulation.
Evidence
No score yet
Safety
Unknown safety profile
Clinical Status
No formal phase listed
Research Sync
Not synced yet
Dosing
Set height & weight in Settings to see your dose.
Pharmacology
Evidence Score
Plain-English Snapshot
Sermorelin is currently categorized as a gh secretagogue compound.
Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.
Safety scoring is incomplete. Start conservatively and monitor carefully.
Core mechanism
GHRH receptor agonist in anterior pituitary somatotrophs; increases cAMP via Gs-coupled receptor; amplifies pulsatile GH release; preserves hypothalamic-pituitary axis
Practical Context
Strongest current signals
No indexed study summaries yet.